Icatibant Stada (Icatibant)

Icatibant works as a competitive antagonist at the bradykinin B2 receptor, a G‑protein‑coupled receptor that mediates vasodilation and increased vascular permeability. When icatibant binds to this receptor, it prevents endogenous bradykinin from activating the signaling cascade, thereby limiting the fluid leakage and swelling that characterize hereditary angioedema attacks.

The dosage of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and additional doses may be given if symptoms persist, following the prescriber’s specific instructions. No standardized dosing regimen is provided here.

Safety data for icatibant in pregnancy and lactation are limited. The product label advises that it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider because it is unknown whether icatibant is excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Icatibant Stada. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved therapies include C1‑inhibitor concentrates (plasma‑derived or recombinant) and kallikrein inhibitors. Icatibant provides a rapid, subcutaneous option that directly blocks bradykinin, while C1‑inhibitor products replace deficient protein and kallikrein inhibitors target upstream activation. Choice of therapy depends on patient preference, attack severity, and physician assessment.

Icatibant should be stored in a refrigerator at 2‑8 °C (36‑46 °F). The product must be kept in its original packaging, protected from light, and must not be frozen or shaken. If a temporary temperature excursion occurs, the vial should be inspected for any changes before use, and any compromised product must be discarded.

Icatibant is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver. The recommended injection site should be rotated for subsequent doses, and the needle should be disposed of in a sharps container following local regulations.

The most serious adverse reactions associated with icatibant include anaphylaxis, severe angioedema, and sudden hypotension, which can be life‑threatening if not treated promptly. Patients should be monitored after the first injection for signs of allergic reaction, and any sudden swelling, difficulty breathing, or drop in blood pressure should trigger immediate medical attention.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal impairment, pregnant or nursing women, and those taking ACE inhibitors or other drugs that increase bradykinin levels, as the risk of angioedema may be heightened. Clinical judgment determines suitability.